Report advocates including Down syndrome individuals in Alzheimer's clinical trials, suggesting treatments could improve their health outcomes by 40%.

A report from the LuMind IDSC Foundation and others highlights that investing in Alzheimer's research for adults with Down syndrome could significantly enhance their quality of life, cut caregiving costs, and extend lifespans by five years. It suggests that treatments developed for the general population could improve health and caregiving outcomes for this group by up to 40%. The report advocates for including individuals with Down syndrome in clinical trials and emphasizes early Alzheimer's detection.

October 01, 2024
5 Articles

Further Reading